---
document_datetime: 2023-09-21 19:53:38
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zalmoxis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zalmoxis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1719785
conversion_datetime: 2025-12-19 12:13:03.310479
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zalmoxis

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended Product Information affected 3 no   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------|-----------|
| IB/0011              | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                      | on 03/08/2018 product               | n/a                                                                        |           |
| II/0009/G            | This was an application for a group of variations. B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection B.II.b.2.c.3 - Change to importer, batch release Medicinal | 26/07/2018                          | Annex II and PL                                                            |           |

<!-- image -->

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method                                                                                                                                                                                                                                                                                                        |                    |            |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|-----------------------------------|
| IB/0012             | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                                                                    | 30/05/2018         | n/a        | authorised                        |
| PSUSA/10530 /201708 | Periodic Safety Update EU Single assessment - allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)                                                                                                                                                                                                                 | 08/03/2018         | n/a longer | PRAC Recommendation - maintenance |
| IB/0007             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                     | 01/03/2018 product | n/a no     |                                   |
| II/0005/G           | This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test Medicinal | 25/01/2018         | n/a        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | procedure                                                                                                                                                                                                                                                                  |                    |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10530 /201702 | Periodic Safety Update EU Single assessment - allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) | 28/09/2017         | n/a               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0003              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                    | 18/05/2017         | 13/07/2017 longer | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit-risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Zalmoxis, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. authorised |
| IB/0002             | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                                           | 08/02/2017 product | n/a no            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0001             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure Medicinal                                                                                                                              | 08/02/2017         | n/a               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |